Is Compounded GLP-1 Legal? Why It Comes Down to the FDA Shortage List

"Is compounded GLP-1 legal?" does not have one permanent answer. It has a rule, and the rule points at a government list that changes. Understanding the mechanism — not a snapshot of today's status — is what lets you tell a compliant provider from one hoping you won't check.

Compounding is legal by design, with one specific limit

Federal law authorizes pharmacy compounding under two sections: 503A for a licensed pharmacist or physician compounding for an individual patient, and 503B for registered "outsourcing facilities" compounding in larger batches under current good manufacturing practice³. Both pathways share one hard limit relevant here: neither may produce a drug that is "essentially a copy" of an FDA-approved product, at scale, as a matter of routine business³⁴. Everything about whether compounded semaglutide or tirzepatide is lawful right now comes down to how that phrase is defined for each pathway — and the definitions are not the same.

For 503A pharmacies: the only exception is a real, individual difference

The statute defining 503A is specific. A drug is not treated as "essentially a copy of a commercially available drug product" only where there is "a change, made for an identified individual patient, which produces for that patient a significant difference, as determined by the prescribing practitioner, between the compounded drug and the comparable commercially available drug product"¹. Notice what is absent: the 503A statute itself does not carve out a general shortage exception. A 503A pharmacy's legal footing for compounding something that looks like Wegovy or Zepbound rests on a documented, patient-specific reason — not on the branded product being hard to find.

For 503B outsourcing facilities: the shortage list is the gate

503B is built differently. An outsourcing facility may compound using a bulk drug substance that is not on FDA's approved clinical-need list only if "the drug compounded from such bulk drug substance appears on the drug shortage list in effect... at the time of compounding, distribution, and dispensing"². The statute's definition of "essentially a copy" repeats the same trigger: a drug that is identical or nearly identical to an approved drug is treated as essentially a copy — and therefore unlawful to mass-produce — "unless... the drug appears on the drug shortage list... at the time of compounding, distribution, and dispensing"². In plain terms: an outsourcing facility's ability to mass-produce something that looks like the brand product exists only while that specific drug sits on FDA's shortage list, checked at the moment of every compounding, distribution, and dispensing event — not once, at signup.

Why this made large-scale compounded semaglutide possible — and why the door can close

This is the actual mechanism behind the compounded-GLP-1 market's growth: when Wegovy, Ozempic, Zepbound, or Mounjaro have appeared on the FDA shortage list, 503B outsourcing facilities gained a lawful path to compound near-identical versions at scale, which is the volume that made low-cost compounded semaglutide and tirzepatide widely available through telehealth. The moment a specific drug and dose come off that list, the statutory gateway for a 503B "copy" of it closes — continuing to sell an essentially-identical version becomes the exact conduct section 503B(a)(5) prohibits². A 503A pharmacy was never operating on that gateway in the first place; its only lawful path to something copy-like was always the individualized-difference exception, shortage or no shortage.

The list moves — verify it yourself

FDA maintains a live, searchable database of current and resolved drug shortages⁵. Status changes, sometimes without much notice to patients, and a provider's landing page is not the record of truth — the database is. Before trusting a "still in shortage" or "shortage has ended, we've adjusted our formula" claim, check the current listing rather than the marketing copy built on top of it.

What to actually ask a compounding provider

Ask which pathway they operate under, 503A or 503B. If 503B, ask how they confirm shortage status at the time of every batch — not just at launch. If 503A, ask what the documented, patient-specific difference is that makes your prescription lawful — a different concentration ordered by your prescriber for a real clinical reason is a legitimate answer; "it's cheaper" or "it's in stock" is not. A provider that cannot answer in plain language is asking you to trust a legal argument it has not actually made.

The same blurred accountability shows up in the syringe

The regulatory ambiguity here is not just theoretical. It is the same environment that let three patients reach a poison control center after receiving compounded semaglutide vials with no pharmacist counseling on dosing units — two of them tenfold overdoses⁶. A pharmacy that is careful about which legal pathway it operates under tends to be the same pharmacy that is careful about what's in the vial and how you're taught to draw it up; our full GLP-1 side-effects review covers that dosing-error risk directly. Sourcing transparency and legal footing are the same trust question asked two ways.

Where this belongs in a provider's grade

This is precisely what the fulfillment dimension of the WeighScore is built to catch — pharmacy sourcing transparency and whether a provider will tell you, plainly, which pharmacy fills your prescription and under which pathway. It sits alongside the broader legitimacy checklist in is compounded semaglutide legit and safe? and the trade-offs laid out in compounded vs. brand-name GLP-1. Price is part of this too — see what compounded GLP-1 actually costs per month for why a rock-bottom quote sitting on shaky legal footing is not the bargain it looks like.

The honest bottom line

"Legal" is not a fixed label stamped on compounded GLP-1 — it is a live status tied to a federal list and, for 503A, to a genuine individualized prescription. A provider that can explain which pathway it uses and answer the shortage-status question without flinching has done real homework. One that changes the subject has told you something too. Compare graded providers on fulfillment and oversight in our reviews and comparisons. None of this is legal or medical advice — a pharmacist, attorney, or licensed clinician should be the one you lean on for a decision specific to you.